Alopecia Areata Market Growth to Hit USD 5.00 billion at a 6.3% CAGR, Globally, by 2030 - Exclusive Report by Data Bridge Market Research

The global Alopecia Areata Market research report conducts an extensive analysis of the Alopecia Areata Market sector and provides information on the state of the market over the forecast period. The winning market research report provides a thorough knowledge of the state of the industry, including historical and anticipated market sizes based on value, volume, and technical growth. It also projects leading and cost-effective market fundamentals. This paper examines the market's potential and prospects from a number of angles, both now and in the future. The comprehensive Alopecia Areata Market report provides numerous market insights through a broad examination of the Alopecia Areata Market industry.

Explore Further Details about This Research Alopecia Areata Market Report https://www.databridgemarketresearch.com/reports/global-alopecia-areata-market

An autoimmune disorder known as alopecia areata causes sporadic hair loss. The National Institute for Health and Care Excellence (NICE) predicted that in 2020, there would be 15 cases of alopecia per 10,000 people in the U.K. Although it can afflict anyone at any age, it is most common in childhood and adolescents. The incidence peaked between the ages of 15 and 29. Before age 21, 50-60% of boys have their first bald spot.

Data Bridge Market Research analyzes that the global alopecia areata market which was USD 3.01 billion in 2022, is likely to reach USD 5.00 billion by 2030, and is expected to undergo a CAGR of 6.3% during the forecast period. "Patchy alopecia areata" dominates the type segment of the myositis treatment market due to the increasing prevalence of hair loss among the population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Alopecia areata (AA) is an autoimmune disease that causes hair to fall out in small, unnoticed patches that eventually become apparent when the hair grows back. When the autoimmune system attaches to the hair follicles, hair loss occurs. Alopecia universalis is a condition that causes total hair loss and prevents hairs from returning. However, the severity of the condition varies from person to person. Hair loss can affect other parts of the body and the face, such as the eyebrows, eyelashes, and beard. When it comes to hair loss, men are more likely than women to have a family history of it.

Drivers

Increasing prevalence of hair loss

The rising prevalence of hair loss is estimated to enhance the alopecia areata market's growth. In 2018, the American Academy of Dermatology Association (AAD) projected that about 50 million men and 30 million women in the United States were plagued with alopecia. According to the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population suffers from hair thinning, with pattern hair loss being the most common in both men and women. Furthermore, roughly 2% of the entire population, regardless of gender, is at risk of acquiring alopecia areata in their lifetime.

Increasing investment in healthcare infrastructure

Another significant factor influencing the growth rate of the alopecia areata market is the rising healthcare expenditure which helps improve its infrastructure. An increase in healthcare expenditure is being driven by an increase in the number of activities conducted by organizations such as the National Alopecia Areata Foundation and the American Hair Loss Association to raise awareness about hair regrowth and treatment alternatives.

Recent Developments

In March 2023, Sun Pharmaceuticals Industries Ltd., a global pharmaceutical company, declared a phase 3 clinical trial data presentation for analyzing deuruxolitinib, an oral medicine to help in improving the scalp hair regrowth in patients with alopecia areata
In June 2023, Pfizer Inc., a multinational biotechnology and pharmaceutical company, notified that the US Food and Administration (FDA) approved LITFULOTM (ritlecitinib), an oral treatment for 12 years and above individuals with severe alopecia areata. This approval resulted in making LITFULOTM an advanced treatment for people with alopecia areata
Global Alopecia Areata Market Scope

The alopecia areata market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Patchy Alopecia Areata
Alopecia Totalis
Alopecia Universalis
Diffuse Alopecia Areata
Ophiasis Alopecia
Others

Treatment

Medical Treatments
Topical agents
Steroid injections
Oral immunosuppressants
Light therapy
Others
Natural Treatment
Herbal supplements
Aromatherapy
Micro-needling
Acupuncture
Probiotics
Others

Diagnosis

Trichoscopy
Skin Biopsy
Others

Route of Administration

Oral
Topical
Parenteral
Others

End-Users

Hospitals
Specialty Clinics
Homecare
Others

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Some of the major players operating in the alopecia areata market are:

Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Eli Lilly and Company (U.S.)
Merck & Co., Inc. (U.S.)
Allergan (Ireland)
AstraZeneca (U.K.)
AbbVie Inc. (U.S.)
Johnson & Johnson Services Inc. (U.S.)
Cipla Inc. (India)  
Abbott (U.S.)
Merck KGaA (Germany)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin Ltd (India)
Hikma Pharmaceuticals PLC (U.K.)
LEO Pharma A/S (Denmark)
Bausch Health Companies Inc. (Canada)
Baxter (U.S.)
Perrigo Company plc (Ireland)

Browse Related Reports:

https://marketsnewsupdate.blogspot.com/2024/03/cholera-treatment-market-with-analysis.html

https://marketsnewsupdate.blogspot.com/2024/03/pemphigus-vulgaris-market-size-share.html

https://marketsnewsupdate.blogspot.com/2024/04/nucleic-acid-based-therapeutics-market.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.